[{"orgOrder":0,"company":"Alcresta Therapeutics","sponsor":"Linden Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"ALC-079","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Alcresta Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcresta Therapeutics \/ Linden Capital Partners","highestDevelopmentStatusID":"1","companyTruncated":"Alcresta Therapeutics \/ Linden Capital Partners"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poseida Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Poseida Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"CN Bio","sponsor":"Cambridge University","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"CN Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"CN Bio \/ Cambridge University","highestDevelopmentStatusID":"1","companyTruncated":"CN Bio \/ Cambridge University"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Licensing Agreement","leadProduct":"ION455","moa":"PNPLA3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Alcresta Therapeutics has developed a novel enzyme-based (iLipase) platform, including ALC-079, which is being investigated for the Neonatal Intensive Care Unit for pancreatic immaturity.

                          Product Name : ALC-079

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          December 03, 2024

                          Lead Product(s) : ALC-079

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Undisclosed

                          Sponsor : Linden Capital Partners

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : As part of the agreement, the companies will combine the optimized delivery of Acuitas' highly validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patients with rare liver disease...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          August 25, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Undisclosed

                          Sponsor : Acuitas

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis (NASH).

                          Product Name : ION455

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          November 23, 2020

                          Lead Product(s) : ION455

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Undisclosed

                          Sponsor : AstraZeneca

                          Deal Size : $330.0 million

                          Deal Type : Licensing Agreement

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The new publication details the potential for the development of EMM compositions that simultaneously target multiple biological pathways and address unmet needs in a range of complex diseases.

                          Product Name : AXA1125

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 30, 2020

                          Lead Product(s) : AXA1125

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The collaborative work uses CN Bio’s NASH model to help elucidate the complex cellular mechanisms that cause liver fibrosis.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 06, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Undisclosed

                          Sponsor : Cambridge University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Data support AXA1665’s potential to address hyperammonemia, amino acid dysregulation and physical dysfunction in subjects with cirrhosis.

                          Product Name : AXA1665

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 17, 2020

                          Lead Product(s) : AXA1665

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Multifactorial liver and systemic biological activity seen for both AXA1125 and AXA1957 in adult subjects with NAFLD at 16 weeks with onset as early as eight weeks.

                          Product Name : AXA1125

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 01, 2020

                          Lead Product(s) : AXA1125

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The expected IPO cash and its series D is earmarked for Poseida's leading candidate P-BCMA-101, an autologous CAR-T currently in a potentially registrational phase 2 trial for multiple myeloma.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 25, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : $110.0 million

                          Deal Type : Public Offering

                          blank

                          09

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Top-line data from AXA1665-002 show dose dependent improvements in markers of cognitive function and amino acid metabolism; both AXA1665 doses safe and well tolerated for 12 Weeks.

                          Product Name : AXA1665

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 08, 2020

                          Lead Product(s) : AXA1665

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : AXA1125-003 is a clinical study assessing the impact of AXA1125 and AXA1957 on safety, tolerability and effects on structures and functions of the liver in adult with nonalcoholic fatty liver disease.

                          Product Name : AXA1125

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 05, 2020

                          Lead Product(s) : AXA1125,AXA1957

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank